TriangleNCT00025506 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From study entry to death or last contact, up to 5 years.
What was measured
The observed length of life from entry into the study to death or the date of last contact.
Analysis population: Eligible and treated patients.
Groups in this outcome
Thalidomide
Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.
| Group | Source count |
|---|---|
| Thalidomide | 45 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Thalidomide | 5.9 | Not reported | 3.6 | 9.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3.6
- upper Limit
- 9.6
- value
- 5.9
- denoms
- counts
- group Id
- OG000
- value
- 45
- units
- Participants
- description
- The observed length of life from entry into the study to death or the date of last contact.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.
- id
- OG000
- title
- Thalidomide
- param Type
- MEDIAN
- population Description
- Eligible and treated patients.
- reporting Status
- POSTED
- time Frame
- From study entry to death or last contact, up to 5 years.
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice